AstraZeneca’s vaccine, dumped by the West, helps fill the demand gap in the rest of the world



PLC’s Covid-19 vaccine is not authorized in the United States, and governments in Canada, Australia and across Western Europe have shunned it after manufacturing problems and rare but sometimes deadly side effects.

However, in most of the rest of the world, it is an important equine vaccine, reaching more people than in middle-income countries and lower than any other vaccine due to this method. Western production. It also has a neck and collar with a shot by China Sinovac Biotechnology Co., Ltd. and one developed by

Pfizer Inc.

and of Germany

BioNTech SE

for globally distributed overall doses.

AstraZeneca has distributed nearly 2.3 billion doses of the drug globally as of mid-December, according to the company. Sinovac said it has delivered more than 2.4 billion doses, compared with Pfizer’s nearly 2.5 billion, according to the company.

Pfizer-BioNTech shot has become priority vaccines in many places can afford it, while AstraZeneca’s photographs, developed with the University of Oxford and a biotech spinout called


PLC, has supplied a large portion to poorer countries.

The International Monetary Fund estimates that low- and middle-income countries overall received 3.25 billion vaccines as of December 11. About half of those — about 1.6 billion doses. — was injected with AstraZeneca, according to data from the IMF and Airfinity Ltd. ., a healthcare and scientific data company. That’s a larger percentage than the dosages of China’s Sinopharm, Sinovac and Pfizer-BioNTech combined, the same data showed.

“The AstraZeneca vaccine is the vaccine,” said Mohga Kamal-Yanni, global health policy expert who advises the People’s Vaccine Alliance, a consortium of health and human rights organizations promoting access to medicines. a lifesaver.

A growing number of studies indicate that Omicron is more resistant to current vaccines than previous Covid-19 variants, although boosters appear to help. WSJ’s Daniela Hernandez gets an exclusive look inside the lab testing how antibodies interact with Omicron. Artwork: Tom Grillo

The Omicron variant spreads fast of Covid-19 has renewed the focus on vaccine shortage in many poorer regions of the world, including Africa. Shipments of many other vaccines, including Pfizer, to poorer regions are growing, according to national officials and public health experts, but the World Health Organization and other public health organizations say shipments are increasing. Other organizations have warned that the focus on boosters in richer countries could exacerbate the problem low vaccination rate in other countries.

From the very beginning, AstraZeneca promise fair access for its vaccines, through manufacturing partnerships around the world. They initially set a goal of delivering 3 billion doses of the drug this year and won’t sell them at a profit as long as the pandemic continues. Footage doesn’t require the supercooled storage required by Pfizer and

Moderna Inc.,

making it easier to distribute in multiple countries.

“We are all very proud company-wide for the impact we have had,” AstraZeneca CEO Pascal Soriot told reporters last month.

AstraZeneca said the vaccine was profitable in the third quarter for the first time, albeit a minuscule number compared to the Covid-19 vaccine profits at Pfizer and Moderna. The company reported $2.2 billion in revenue from vaccines for the year through September start pricing for profit to some buyers, but is still selling at original prices to lower income countries.

The vaccine’s global distribution volumes and third-quarter profits represent a significant change from the start of the year. AstraZeneca executives have struggled to deal with massive production shortages around the world while lose money for effort.

Blood clots are rare but sometimes deadly associated with vaccines avoid the shot in many European countries. More recently, the UK dropped all homegrown targets as part of their boosted push. Government advisers, who have accompanied Pfizer and Moderna as boosters, say an mRNA vaccine is likely to provide the best possible additional protection. They are also reluctant are more likely to have blood clotting problems in people who have not received AstraZeneca, according to vaccine researchers and others briefed on the government’s decision.


AstraZeneca’s vaccine has been rejected by many European countries in part because it is very rare but sometimes fatal due to blood clots.


sashenka gutierrez / Shutterstock

Shooting of AstraZeneca is not yet authorized in the US, although the drug’s maker has said earlier it still plans to seek full approval there by the end of the year. Companies have struggling to compile all the necessary data for regulators, The Wall Street Journal reported, and has repeatedly missed its own target deadline to obtain regulatory approval for footage for use in the US

Earlier this year, European politicians who had initially placed big bets on AstraZeneca for their vaccinations began to double the dose of Pfizer. More affluent countries are also beginning to restrict the use of AstraZeneca injections as more and more scrutiny comes into the country’s rare blood clotting problems.

All of these have contributed to creating a wave of AstraZeneca vaccine donation government of the United States, Canada, Australia and Western Europe for poorer countries.

AstraZeneca gradually settled its global production problems. According to Adar Poonawalla, managing director of Serum, by far the largest manufacturer in its partnership network, Serum Institute of India, has provided more than 1.3 billion doses of vaccine for about 70 nation. He said in an interview after India restricted exports amid its own wave of infections, most of the serum-produced doses – nine out of 10 – remained in India. Degree. The delayed supply that other low-income countries are counting on.

“When you add in the benefits to humanity, I think you’ll see that the vaccine has quite the effect on the health that it has prevented and the deaths it has prevented.”

– John Bell, a senior Oxford scholar

The serum can produce 250 million doses of the vaccine a month, Mr. Poonawalla said, but the company has cut it back by about half this month amid lower demand. He expects the drop to be temporary while countries absorb dose increases from other vaccine makers, including Pfizer. The Serum Institute is working on selling the new vaccine directly to individual countries, he said.

John Bell, an Oxford senior scholar, who last year guided the university through negotiations for a vaccine partnership with AstraZeneca.

Real-world observations, including data from the UK, have shown AstraZeneca . footage effective in preventing severe Covid-19 and death. AstraZeneca and researchers from Oxford say that recently, laboratory studies have found a third dose of the vaccine. increased antibody protection against Omicron from levels achieved from two doses. Studies, not peer-reviewed, may support the use of footage as an enhancer.

Write letter for Jenny Strasburg at

Copyright © 2021 Dow Jones & Company, Inc. All rights reserved. 87990cbe856818d5eddac44c7b1cdeb8 AstraZeneca’s vaccine, dumped by the West, helps fill the demand gap in the rest of the world

Ian Walker is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials, please contact us by email – The content will be deleted within 24 hours.

Related Articles

Back to top button